Immunoglobulin Dosage and Administration Form in CIDP and MMN

Inclusion Criteria: * Diagnosed with CIDP or MMN fulfilling the EFNS/PNS criteria * Maintenance treatment with IVIG or SCIG for at least 3 months * Negative result on a pregnancy test (HCG-based assay in urine) for women of childbearing potential and use of a reliable method of contraception for the duration of the study Exclusion Criteria: * Pure sensory or severe ataxic CIDP * Other cause of neuropathy (incl. pressure neuropathy) * Known history of adverse reactions to IgA in other products * Exposure to blood or any blood product or plasma derivatives, other than Privigen, within the past 3 months prior to first infusion of Gammanorm * Ongoing history of hypersensitivity or persistent reactions to blood or plasma derived products. * Requirement of any routine premedication for IgG administration * History of malignancies of lymphoid cells and immunodeficiency with lymphoma * Severe liver function impairment (ALAT 3 times above upper limit of normal) * Known protein-losing enteropathies or proteinuria. * Live viral vaccination (such as measles, rubella, mumps and varicella) within the last 2 months prior to first infusion of Gammanorm * Treatment with any investigational medicinal product within 3 months prior to first infusion of Gammanorm * Medication interfering with hematopoiesis * Other immunomodulation therapy than low dose steroid (Prednisolone \< 25 mg daily) * Known or suspected to abuse alcohol, drugs, psychotropic agents or other chemicals within the past 12 m…